{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:02:34Z","timestamp":1777658554827,"version":"3.51.4"},"reference-count":55,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Global Qualitative Nursing Research"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:p>Continuous subcutaneous insulin infusion (CSII) is a complex, medical device for the management of Type 1 Diabetes Mellitus (T1DM). There is limited research exploring the everyday experiences living with this device. The purpose of this study was to understand the lived experience of adults using CSII therapy to manage T1DM. Lived experiences from eight individuals were collected through semi-structured interviews and then analyzed using a hermeneutic approach to phenomenology. Four substantive themes with supporting subthemes were identified and represent the essence of participant experiences; that is, living with CSII eventually took ascendancy over managing T1DM.CSII therapy has gained popularity due to reported improvements in metabolic control and flexibility. However, the burden of the responsibility and psychological implications of CSII took ascendancy over T1DM. Living with CSII impacts the psychological well-being of individuals so psychological complications are as important to assess by healthcare professionals as physical and metabolic complications.<\/jats:p>","DOI":"10.1177\/2333393620981058","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T05:41:57Z","timestamp":1630647717000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["The Lived Experience of Continuous Subcutaneous Insulin Infusion in Adults With Type 1 Diabetes Mellitus: A Phenomenological Inquiry"],"prefix":"10.1177","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0784-2334","authenticated-orcid":false,"given":"V. Renee","family":"Callahan Fagan","sequence":"first","affiliation":[{"name":"Memorial University of Newfoundland, St. John\u2019s, NL, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Parsons","sequence":"additional","affiliation":[{"name":"Memorial University of Newfoundland, St. John\u2019s, NL, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,9,3]]},"reference":[{"key":"bibr1-2333393620981058","doi-asserted-by":"crossref","unstructured":"Aberle I., Scholz U., Kliegel B. B., Fischer C., Gorny M., Kliegel M. (2009). Psychological aspects in continuous subcutaneous insulin infusion: A retrospective study. The Journal of Psychology, 143, 147\u2013160. https:\/\/doi.org\/10.3200\/JRLP.143.2.147-160","DOI":"10.3200\/JRLP.143.2.147-160"},{"key":"bibr2-2333393620981058","doi-asserted-by":"crossref","unstructured":"Balfe M., Doyle F., Smith D., Sreenan S., Brugha R., Hevey D., Conroy R. (2013). What\u2019s distressing about having type I diabetes? A qualitative study of young adults\u2019 perspectives. BMC Endocrine Disorders, 13, 1\u201314. https:\/\/doi.org\/10.1186\/1472-6823-13-25","DOI":"10.1186\/1472-6823-13-25"},{"key":"bibr3-2333393620981058","doi-asserted-by":"crossref","unstructured":"Barnard K. D., Lloyd C. E., Skinner T.C. (2007). Systematic literature review: Quality of life associated with insulin pump use in type I diabetes. Diabetic Medicine, 24, 607\u2013614. https:\/\/doi.org\/10.1111\/j.1464-5491.2007.02120.x","DOI":"10.1111\/j.1464-5491.2007.02120.x"},{"key":"bibr4-2333393620981058","doi-asserted-by":"crossref","unstructured":"Barnard K. D., Skinner T. C. (2007) Qualitative study into quality of life issues surrounding insulin pump use in type I diabetes. Practical Diabetes International, 24, 143\u2013148. https:\/\/doi.org\/10.1002\/pdi.1079","DOI":"10.1002\/pdi.1079"},{"key":"bibr5-2333393620981058","doi-asserted-by":"crossref","unstructured":"Barnard K. D., Skinner T. C. (2008) Cross-sectional study into quality of life issues surrounding insulin pump use in type I diabetes. Practical Diabetes International, 25, 194\u2013200. https:\/\/doi.org\/10.1002\/pdi.1079","DOI":"10.1002\/pdi.1248"},{"key":"bibr6-2333393620981058","doi-asserted-by":"crossref","unstructured":"Bode B. W., Sabbah H. T., Gross T. M., Fredrickson L. P., Davidson P. C. (2002). Diabetes management in the new millennium using insulin pump therapy. Diabetes Metabolism Research and Reviews, 18\n                      Suppl I\n                      , S14\u2013S20. https:\/\/doi.org\/10.1002\/dmrr.205","DOI":"10.1002\/dmrr.205"},{"key":"bibr7-2333393620981058","doi-asserted-by":"crossref","unstructured":"Bruttomesso D., Costa S., Baritussio A. (2009). Continuous subcutaneous insulin infusion (CSII) 30 years later: Still the best option for insulin therapy. Diabetes Metabolism Research and Review, 25, 99\u2013111. https:\/\/doi.org\/10.1002\/dmrr.931","DOI":"10.1002\/dmrr.931"},{"key":"bibr8-2333393620981058","unstructured":"Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, and Social Sciences and Humanities Research Council of Canada,\n                      Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans\n                      , December 2014. http:\/\/www.pre.ethics.gc.ca\/pdf\/eng\/tcps2-2014\/TCPS_2_FINAL_Web.pdf"},{"key":"bibr9-2333393620981058","doi-asserted-by":"crossref","unstructured":"Clements M., Matuleviciene V., Attvall S., Eckland M., Pivodic A., Dahlqvist S., Fahl\u00e9n M., Haraldsson B., Lind M. (2015). Predicting the effectiveness of insulin pump therapy on glycemic control in clinical practice: A retrospective study of patients with type I diabetes from 10 outpatient diabetes clinics in Sweden over 5 years. Diabetes Technology and Therapeutics, 17, 21\u201328. https:\/\/doi.org\/10.1089.dia.2014.0139","DOI":"10.1089\/dia.2014.0139"},{"key":"bibr10-2333393620981058","doi-asserted-by":"crossref","unstructured":"Dahan A., McAfee S.G. (2009). A proposed role for the psychiatrist in the treatment of adolescents with type I diabetes. The Psychiatric Quarterly, 80, 75\u201385. https:\/\/doi.org\/10.1007\/S11126-009-9099-1","DOI":"10.1007\/s11126-009-9099-1"},{"key":"bibr11-2333393620981058","doi-asserted-by":"crossref","unstructured":"Franklin V. (2016). Influence on technology use and efficacy in type I diabetes. Journal of Diabetes Science and Technology, 10, 647\u2013655. https:\/\/doi.org\/10.1177\/1932296816639315","DOI":"10.1177\/1932296816639315"},{"key":"bibr12-2333393620981058","doi-asserted-by":"crossref","unstructured":"Garmo A., Hornsten A., Leksell J. (2013). \u201cThe pump was a saviour for me.\u201d Patients\u2019 experiences of insulin pump therapy. Diabetic Medicine, 6, 717\u2013723. https:\/\/doi.org\/10.1111\/dme.12155","DOI":"10.1111\/dme.12155"},{"key":"bibr13-2333393620981058","doi-asserted-by":"crossref","unstructured":"Gim\u00e9nez M., Conget I., Jans\u00e0 M., Vidal M., Chiganer G., Levy I. (2007). Efficacy of continuous subcutaneous insulin infusion in type I diabetes: A 2 year perspective using the established criteria for funding from a national health service. Diabetic Medicine, 24, 1419\u20131423. https:\/\/doi.org\/10.1111\/j.1464-5491.2007.02287.x","DOI":"10.1111\/j.1464-5491.2007.02287.x"},{"key":"bibr14-2333393620981058","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S45156"},{"key":"bibr15-2333393620981058","doi-asserted-by":"crossref","unstructured":"Hammond P., Boardman S., Greenwood R. (2006) ABCD position paper on insulin pumps. Practical Diabetes International, 23, 395\u2013400. https:\/\/doi.org\/10.1002.pdi.1023","DOI":"10.1002\/pdi.1023"},{"key":"bibr16-2333393620981058","doi-asserted-by":"crossref","unstructured":"Hanaire H. (2011). External insulin pump treatment in the day-to-day management of diabetes: benefits and future prospectives. Diabetes & Metabolism, 37, S40\u2013S47. https:\/\/doi.org\/10.1016\/S1262-3636(11)70964-8","DOI":"10.1016\/S1262-3636(11)70964-8"},{"key":"bibr17-2333393620981058","doi-asserted-by":"crossref","unstructured":"Hayes M., Frearson S., Keller C., Cartmale A., Lewis-Hayes S. (2011). A hermeneutic phenomenological study of why adults with type I diabetes choose to discontinue CSII. European Diabetes Nursing, 8, 12\u201316. https:\/\/doi.org\/10.1002\/edn.167","DOI":"10.1002\/edn.167"},{"key":"bibr18-2333393620981058","volume-title":"Being and Time","author":"Heidegger M.","year":"1927"},{"key":"bibr19-2333393620981058","doi-asserted-by":"crossref","unstructured":"Heinemann L., Krinelke L. (2012). Insulin infusion set: The Achilles heel of subcutaneous insulin infusion. Journal of Diabetes Science and Technology. 4, 954\u2013964. https:\/\/doi.org\/10.1177\/193229681200600429","DOI":"10.1177\/193229681200600429"},{"key":"bibr20-2333393620981058","doi-asserted-by":"crossref","unstructured":"Heinemann L., Waldenmaier D., Kulzer B., Ziegler R., Ginsberg B., Freckmann G. (2018). Patch pumps: Are they all the same? Journal of Diabetes Science and Technology, 13, 34\u201340. https:\/\/doi.org\/10.1177\/1932296818795150","DOI":"10.1177\/1932296818795150"},{"key":"bibr21-2333393620981058","doi-asserted-by":"crossref","unstructured":"Hood D. G., Duke G. (2015). The nature and meaning of inulin pump use in emerging adults with type 1 diabetes. Diabetes Spectrum, 28, 75\u201381. https:\/\/doi.org\/10.2337\/diaspect.28.2.75","DOI":"10.2337\/diaspect.28.2.75"},{"key":"bibr22-2333393620981058","doi-asserted-by":"crossref","unstructured":"Joshi M., Choudhary P. (2015). Multiple daily injections or insulin pump therapy: Choosing the best option for your patient \u2013 An evidence-based approach. Current Diabetes Report, 15, 1\u20136. https:\/\/doi.org\/10.1007\/s11892-015-0644-z","DOI":"10.1007\/s11892-015-0644-z"},{"key":"bibr23-2333393620981058","doi-asserted-by":"crossref","unstructured":"Kay C., Davies J., Gamsu D., Jarman M. (2009). An exploration of the experiences of young women living with type 1 diabetes. Journal of Health Psychology, 14, 242\u2013250. https:\/\/doi.org\/10.1177\/1359105308100208","DOI":"10.1177\/1359105308100208"},{"key":"bibr24-2333393620981058","doi-asserted-by":"crossref","unstructured":"Kerr D., Nicholls H., James J. (2008) Continuous subcutaneous insulin infusion (CSII insulin pump therapy) for type I diabetes: A Bournemouth perspective. Practical Diabetes International, 25, 114\u2013117. https:\/\/doi.org\/10.1002\/pdi.1213","DOI":"10.1002\/pdi.1224"},{"key":"bibr25-2333393620981058","doi-asserted-by":"crossref","unstructured":"Lee S.W., Im R., Magbual R. (2004) Current perspectives on the use of continuous subcutaneous insulin infusion in the acute care setting and overview of therapy. Critical Care Nursing, 27, 172\u2013184. https:\/\/doi.org\/10.1097\/00002727-20040404000-0009","DOI":"10.1097\/00002727-200404000-00009"},{"key":"bibr26-2333393620981058","unstructured":"Lilly A. L. (2004). The lived experience of type I diabetes in adulthood: A phenomenological study. (Unpublished Master\u2019s Thesis). Memorial University of Newfoundland, St. John\u2019s, NL."},{"key":"bibr27-2333393620981058","doi-asserted-by":"crossref","unstructured":"McAdams B. H., Rizvi A. A. (2016) An overview of insulin pumps and glucose sensors for the generalist. Journal of Clinical Medicine, 5, 1017. https:\/\/doi.org\/10.3390\/jcm5010005","DOI":"10.3390\/jcm5010005"},{"key":"bibr28-2333393620981058","volume-title":"Phenomenology of perception","author":"Merleau-Ponty M.","year":"1962"},{"key":"bibr29-2333393620981058","doi-asserted-by":"crossref","unstructured":"Misso M. L., Egberts K. J., Page M., O\u2019Connor D., Shaw J. (2010). Continuous subcutaneous insulin infusion (CSII) versus multiple daily injections for Type I diabetes mellitus. The Cochrane Database of Systematic Reviews, 2010 (1), 1\u2013139. https:\/\/doi.org\/10.1002\/14651858.CD005103.pub2","DOI":"10.1002\/14651858.CD005103.pub2"},{"key":"bibr30-2333393620981058","doi-asserted-by":"crossref","unstructured":"Nathan D. M. (2014). The diabetes control and complications trial\/epidemiology of diabetes interventions and complications study at 30 years: Overview. Diabetes Care, 37, 9\u201316. https:\/\/doi.org\/10.2337\/dc13-2112","DOI":"10.2337\/dc13-2112"},{"key":"bibr31-2333393620981058","unstructured":"Neithercott T. (2013, January).\n                      Diabetes forecast\n                      : Using an insulin pump and a CGM. http:\/\/www.diabetesforecast.org\/2013\/jan\/cgms-and-insulin-pumps-2013.html."},{"key":"bibr32-2333393620981058","doi-asserted-by":"crossref","unstructured":"Nicolucci A, Maione A, Franciosi M, Amoretti R, Busetto E, Capani F., Bruttomesso D., Di Bartolo P., Girelli A., Leonetti F., Morviducci L., Ponzi P., Vitacolonna E. (2008). Quality of life and treatment satisfaction in adults with type I diabetes: A comparison between continuous subcutaneous insulin infusion and multiple daily injections. Diabetic Medicine, 25, 213\u2013220. https:\/\/doi.org\/10.1111\/j.1464-5491.2007.02346.x","DOI":"10.1111\/j.1464-5491.2007.02346.x"},{"key":"bibr33-2333393620981058","doi-asserted-by":"crossref","unstructured":"Pickup J., Keen H. (2002). Continuous subcutaneous insulin infusion at 25 years: Evidence base for the expanding use of insulin pump therapy in type I diabetes. Diabetes Care, 25, 593\u2013598. https:\/\/doi.org\/10.2337\/diacare.25.3.593","DOI":"10.2337\/diacare.25.3.593"},{"key":"bibr34-2333393620981058","doi-asserted-by":"crossref","unstructured":"Pickup J. C., Hammond P. (2009). NICE guidance on continuous subcutaneous insulininfusion 2008: Review of the technology appraisal guidance. Diabetic Medicine, 26, 1\u20134. https:\/\/doi.org\/10.1111\/j.1464-5491.2008.02617.x","DOI":"10.1111\/j.1464-5491.2008.02617.x"},{"key":"bibr35-2333393620981058","doi-asserted-by":"crossref","unstructured":"Pickup J. C., Sutton J. (2008). Severe hypoglycemia and glycemic control in type I diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabetic Medicine, 25, 765\u2013774. https:\/\/doi.org\/10.1111\/j.1464-5491-2008.02486.x","DOI":"10.1111\/j.1464-5491.2008.02486.x"},{"key":"bibr36-2333393620981058","doi-asserted-by":"crossref","unstructured":"Pozzilli P., Battelino T., Danne T., Hovorka R., Jarosz-Chobot P., Renard E. (2016). Continuous subcutaneous insulin infusion in diabetes; patient populations, safety, efficacy, and pharmacoeconomics. Diabetes Metabolism Research and Reviews, 32, 21\u201339. https:\/\/doi.org\/10.1002\/dmrr.2653","DOI":"10.1002\/dmrr.2653"},{"key":"bibr37-2333393620981058","doi-asserted-by":"crossref","unstructured":"Rasmussen B., Ward G., Jenkins A., King S. J., Dunning T. (2011). Young adults\u2019 management of type I diabetes during life transitions. Journal of Clinical Nursing, 20, 1981\u20131992. https:\/\/doi.org\/10.1111\/j.1365-2702.2010,03657.x","DOI":"10.1111\/j.1365-2702.2010.03657.x"},{"key":"bibr38-2333393620981058","doi-asserted-by":"crossref","unstructured":"Reidy C., Bracher M., Foster C., Vassilev I., Rogers A. (2018). The process of incorporating insulin pumps into the everyday lives of people with type 1 diabetes: A critical interpretative synthesis. Health Expectations, 21, 1\u201316. https:\/\/doi.org\/10.1111\/hex.12666","DOI":"10.1111\/hex.12666"},{"key":"bibr39-2333393620981058","doi-asserted-by":"crossref","unstructured":"Rintala T. M., Pasvilainen E., Astedt-Kurki P. (2013). Everyday living with diabetes described by family members of adult people with Type 1 diabetes. International Journal of Family Medicine, 2013, 1\u20138. https:\/\/doi.org\/10.1155\/2013\/967872","DOI":"10.1155\/2013\/967872"},{"key":"bibr40-2333393620981058","doi-asserted-by":"crossref","unstructured":"Ritholz M. D., Smaldone A., Lee J., Castille A., Wolpert H., Weinger K. (2007). Perceptions of psychosocial factors and the insulin pump. Diabetes Care, 30, 549\u2013554. https:\/\/doi.org\/10.2337\/dc06.1755","DOI":"10.2337\/dc06-1755"},{"key":"bibr41-2333393620981058","doi-asserted-by":"crossref","unstructured":"Robinson D. J., Coons M., Haensel H., Vallis M., Vale J. F. (2018). Diabetes and mental health. Canadian Journal of Diabetes, 42, S130\u2013S141. https:\/\/doi.org\/10.1016\/j.jcjd.2017.10.031","DOI":"10.1016\/j.jcjd.2017.10.031"},{"key":"bibr42-2333393620981058","doi-asserted-by":"crossref","unstructured":"Rodrigues I. A., Reid H. A., Ismail K., Amiel S. A. (2005). Indications and efficacy of continuous subcutaneous insulin infusion (CSII) therapy in type 1 diabetes mellitus: A clinical audit in a specialist service. Diabetes Medicine, 22, 842\u2013849. https:\/\/doi.org\/10.1111\/j.1399-5448.2008.00441.x","DOI":"10.1111\/j.1464-5491.2005.01539.x"},{"key":"bibr43-2333393620981058","doi-asserted-by":"crossref","unstructured":"Saarinen T., Fernstrom L., Brorsson A., Olinder A. L. (2014). Insulin pump therapy is perceived as liberating but to many it can imply a sense of the diabetes made visible. European Diabetes Nursing, 11, 38\u201342. https:\/\/doi.org\/10.1002\/edn.246","DOI":"10.1002\/edn.246"},{"key":"bibr44-2333393620981058","doi-asserted-by":"crossref","unstructured":"Saboo B. D., Talaviya P. A. (2012). Continuous subcutaneous insulin infusion: Practical issues. Indian Journal of Endocrinology Metabolism, 16, S259\u2013S262. https:\/\/doi:10.4103\/2230-8210.104055","DOI":"10.4103\/2230-8210.104055"},{"key":"bibr45-2333393620981058","volume-title":"Being and nothingness","author":"Sartre J. -P.","year":"1956"},{"key":"bibr46-2333393620981058","doi-asserted-by":"crossref","unstructured":"Scheidegger U., Allemann S., Scheidegger K., Diem P. (2007). Continuous subcutaneous insulin infusion therapy: Effects on quality of life. Swiss Medical Weekly, 137, 476\u2013482. https:\/\/doi.org\/2007\/33\/smw-11588","DOI":"10.4414\/smw.2007.11588"},{"key":"bibr47-2333393620981058","doi-asserted-by":"crossref","unstructured":"Shalitin S., Gil M., Nimri R., de Vries L., Gavan M.Y., Phillip M. (2010). Predictors of glycaemic control in patients with type I diabetes commencing continuous subcutaneous insulin infusion therapy. Diabetic Medicine, 27, 339\u2013347. https:\/\/doi.org\/10.1111\/j.1464-5491.2009.02925","DOI":"10.1111\/j.1464-5491.2009.02925.x"},{"key":"bibr48-2333393620981058","doi-asserted-by":"crossref","unstructured":"Thabit H., Hovorka R. (2016). Continuous subcutaneous insulin infusion therapy and multiple daily insulin injections in Type I diabetes mellitus: A comparative overview and future horizons. Expert Opinion on Drug Delivery, 13, 389\u2013400. https:\/\/doi.org\/10.1517\/17425247.2016.1115013","DOI":"10.1517\/17425247.2016.1115013"},{"key":"bibr49-2333393620981058","doi-asserted-by":"crossref","unstructured":"The Diabetes Control and Complications Trial Research Group. (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The New England Journal of Medicine, 339, 977\u2013986. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8366922","DOI":"10.1056\/NEJM199309303291401"},{"key":"bibr50-2333393620981058","doi-asserted-by":"crossref","unstructured":"Thompson B., Cook C. B. (2019). Insulin pumping patches: Emerging insulin delivery systems. Journal of Diabetes Science and Technology, 13, 8\u201310. https:\/\/doi.org\/0.1177\/1932296818814541","DOI":"10.1177\/1932296818814541"},{"key":"bibr51-2333393620981058","doi-asserted-by":"crossref","unstructured":"Todres L., Keen S., Kerr D. (2010). Continuous subcutaneous insulin infusion in type 1 diabetes: Patient experiences of \u2018living with a machine.\u2019 Diabetic Medicine, 27, 1201\u20131204. https:\/\/doi.org\/10.1111\/j.1464-5491.2010.03058.x","DOI":"10.1111\/j.1464-5491.2010.03058.x"},{"key":"bibr52-2333393620981058","doi-asserted-by":"crossref","unstructured":"Trief P. M., Sandberg J. G., Dimmock J. A., Forken P. J., Weinstock R. S. (2013). Personal and relationship challenges of adults with type I diabetes. Diabetes Care, 36, 2483\u20132488. https:\/\/doi.org\/10.2337\/dcl2-1718","DOI":"10.2337\/dc12-1718"},{"key":"bibr53-2333393620981058","volume-title":"Researching lived experience: Human science for an action sensitive pedagogy","author":"van Manen M","year":"1990"},{"key":"bibr54-2333393620981058","volume-title":"Researching lived experience: Human science for an action sensitive pedagogy","author":"van Manen M","year":"1997","edition":"2"},{"key":"bibr55-2333393620981058","unstructured":"Wood L. (2011, August 25). Business Wire: Research and markets: US insulin delivery devices market: An analysis. http:\/\/www.businesswire.com\/news\/home\/20110825005874\/en\/Research-Markets-Insulin-Delivery-Devices-Market-Analysis."}],"container-title":["Global Qualitative Nursing Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2333393620981058","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2333393620981058","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2333393620981058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:14:15Z","timestamp":1777446855000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2333393620981058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":55,"alternative-id":["10.1177\/2333393620981058"],"URL":"https:\/\/doi.org\/10.1177\/2333393620981058","relation":{},"ISSN":["2333-3936","2333-3936"],"issn-type":[{"value":"2333-3936","type":"print"},{"value":"2333-3936","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"article-number":"2333393620981058"}}